Why is Bharat Immunolog falling/rising?

As of 11-Jul, Bharat Immunological & Biological Corporation Ltd is currently priced at 23.06, reflecting a rise of 0.11 or 0.48%. Despite this slight increase, the stock has shown a significant decline over the past week, down 3.47%, and has underperformed the benchmark Sensex, which decreased by only 1.12% in the same period. The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. However, there has been a notable increase in investor participation, with delivery volume rising by 255.09% against the 5-day average. The company's long-term fundamentals are weak, as it has not declared results in the last six months, and its net sales and operating profit have seen drastic declines over the past five years.
In the broader market context, while Bharat Immunological's stock has experienced a decline of 11.31% over the past month and 19.06% over the past year, the Sensex has remained relatively stable, with only a 0.02% change over the month and a 3.26% increase over the year. This consistent underperformance against the benchmark highlights the company's struggles, particularly in light of negative financial results reported for the first nine months of the year, which showed an 87.03% decline in net sales and a significant loss in profit after tax. The stock's risk is further compounded by its high debt-to-EBITDA ratio and the absence of recent financial disclosures, making it a risky investment compared to its historical valuations.